Biomarker ID | 1064 |
PMID | 23377530 |
Year | 2013 |
Biomarker | miR-141 |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in Bone Metastasis |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:- regulation of RNA metabolic process; Gene expression (Transcription); RNA Polymerase II Transcription; nuclear chromosome; DNA-binding transcription factor activity, RNA polymerase II-specific |
Experiment | Patients with Bone Metastasis Vs No Bone Metastasis |
Type of Biomarker | Prognostic |
Cohort | 10 patients with Benign Prostatic Hyperplasia (BPH), 20 with Local Prostate Cancer, 30 with bone-metastatic PCa (10 with hormone-naive PCa (HNPC) , 10 with hormone-sensitive PCa (HSPC) and 10 with hormone-refractory PCa (HRPC)) were taken for the study |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | NA |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | miR-141 |